HLA-A and myeloid sarcoma: In this context, several studies highlighted how the presence of the MS‐deleterious allele HLA‐DRB1*15:01 and the absence of the MS‐protective HLA‐A*02:01 synergistically amplify MS risk in EBV‐infected individuals with IM history [10, 11, 12].